MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta

MapLight pauses preclinical work to focus on ML-007C-MA for schizophrenia; ADC Therapeutics weighs Zynlonta's future after FDA flags safety concerns in LOTIS-5 trial.

Raccontata daendpoints.news